Erasca (ERAS) Net Cash Flow (QoQ) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -842.63% |
| Dec 31, 2025 | -12.53% |
| Sep 30, 2025 | 194.19% |
| Jun 30, 2025 | -258.18% |
| Mar 31, 2025 | 339.35% |
| Dec 31, 2024 | 98.90% |
| Sep 30, 2024 | -208.16% |
| Jun 30, 2024 | 687.66% |
| Mar 31, 2024 | 17.38% |
| Dec 31, 2023 | 23.68% |
| Sep 30, 2023 | 80.65% |
| Jun 30, 2023 | -1,068.91% |
| Mar 31, 2023 | -117.64% |
| Dec 31, 2022 | 182.49% |
| Sep 30, 2022 | -122.83% |
| Jun 30, 2022 | -30.21% |
| Mar 31, 2022 | 68.19% |
| Dec 31, 2021 | -129.48% |
| Sep 30, 2021 | 2,229.15% |
| Jun 30, 2021 | -112.98% |
| Mar 31, 2021 | 3,017.27% |
| Dec 31, 2020 | 108.00% |